ESH AL 2018 | Combination therapy for the treatment of AML
Christoph Röllig
• 4 May 2018
Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, explains how the lack of novel drugs for the treatment of acute myeloid leukemia (AML) in the past 50 years has led to increased research into combination therapy using existing drugs. Different dosing schedules of available AML drugs are now being used to improve patient outcomes, but extensive research into new therapies is needed to further increase response rates. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
